We report that antisense phosphorothioate oligodeoxyribonucleotides (PS-ODNs) against cyclic AMP response elementbinding protein (CREB) induce the death of human leukemia cell lines including HL-60, Kasumi-1 and K562, OCI-AML1a and also primary leukemia cells isolated from patients with acute myelocytic leukemia and chronic myelocytic leukemia in blastic crisis. In contrast, normal human bone marrow CD34 + cells and normal peripheral blood lymphocytes were resistant to the antisense-mediated cell death. We found that antisense-treated HL-60 cells had prominent nuclear fragmentations but lacked apoptotic features including internucleosomal DNA cleavage and TUNEL positivity. Cell cycle analysis demonstrated a remarkable reduction in G1 phase population along with a mild accumulation of S phase and good preservation of G2/M phase, indicating cells died at G2/M without cycling into G1 phase. None of the sense-sequenced PS-ODNs induced cell death. Further, neither the expression nor the message of CREB protein was reduced by antisense treatment, indicating that cell death was mediated by a non-antisense mechanism. On the other hand, no consensus oligonucleotide sequence for cell death induction was detected. Rather, we found a good correlation between the melting temperatures and the anti-proliferative activities of the oligonucleotides. Thus, CREB antisense PS-ODNs selectively induce a non-apoptotic cell death in leukemic cells by an unknown hybridization-dependent mechanism. Leukemia (2001) 15, 238-245.
Introduction
In the course of our study for the role of cyclic AMP response element-binding protein (CREB), a cyclic AMP-dependent transcription factor [1] [2] [3] being involved in cell survival control in certain tissues, [4] [5] [6] in hematopoietic cell growth by using an antisense strategy, we unexpectedly found that CREB antisense phosphorothioate oligodeoxyribonucleotides (PSODNs) specifically induced leukemia cell death by a bizarre non-antisense mechanism.
Concerning the non-specific or non-antisense growth inhibitory effects of PS-ODNs, two mechanisms have been proposed (reviewed by Clark 7 ) . One is the non-specific cytotoxicity of degradation products of PS-ODNs. [8] [9] [10] [11] Because CREB sense PS-ODNs and the shorter antisense PS-ODNs had no inhibitory effects on leukemic cell growth and because normal hematopoietic cells are resistant to CREB antisense PSODNs-mediated cell death, this possibility could not be the case. The other one is a sequence-specific mechanism (ie an aptameric mechanism) of PS-ODNs as reported in cases of bcr-abl, 12 c-myc 13 and c-myb, 13, 14 and human immunodefi- ciency virus (HIV), 15 where particular short nucleotide sequences were shown to be responsible for their anti-proliferative effects. This aptameric effect is also unlikely in CREB antisense PS-ODN-mediated growth inhibition, because there was no consensus sequence detected for growth suppression. Interestingly, the growth inhibitory effects of PS-ODNs depended on their hybridization potential to the CREB message.
In this paper, we propose a putative novel mechanism for growth inhibition by CREB antisense PS-ODNs. We also discuss their possible application for leukemia therapy, which would have least toxic effects on normal hematopoiesis.
Materials and methods

Cells
HL-60, K562 and Kasumi-1 cells were maintained in RPMI 1640 medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (JRH Bioscience, Lenexa, KS, USA). OCI-AML1a cells, which were kindly provided by Professor Nobuo Nara (Tokyo Medical and Dental University), were maintained in ␣-MEM (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum. The bone marrow samples were obtained from two informed and consenting patients, one with acute myelocytic leukemia (AML) at the Hospital of International Medical Center of Japan and the other with chronic myelocytic leukemia (CML) in blastic crisis at NTT Kanto Medical Center. The mononuclear cell fraction, consisting of the leukemia cells, was prepared using Lymphoprep (Nycomed Pharma, Oslo, Norway). Normal CD34 + cells were purchased from Biowhittaker Acambrex (Gaithersburg, MD, USA) and cultured with Iscove's modified Dulbecco's medium (Life Technologies) supplemented with 20% fetal calf serum and 100 ng/ml of interleukin-3 (Pepro Tech, Rocky Hill, NJ, USA) and stem cell factor (Pepro Tech). Thirty ml of peripheral blood was obtained from a normal volunteer. The mononuclear cells were separated by Lymphoprep and the lymphocyte fraction was further purified by centrifugal elutriation in a Hitachi SRR6Y elutriation rotor (Hitachi, Tokyo, Japan). The lymphocytes were cultured with RPMI 1640 medium supplemented with 10% fetal calf serum and 20 l/ml of phytohemaggulutinin-M (PHA-M) (Difco Laboratories, Detroit, MI, USA). To examine the effects of oligonucleotides, 1 ml culture of HL-60, K562 and OCI-AML1a (at the density of 2 × 10 4 /ml), Kasumi-1 cells (at the density of 1 × 10 5 /ml), primary leukemia cells, normal CD34
+ cells (at the density of 3.5 × 10 4 /ml) and the peripheral blood mononuclear cells (at the density of 1 × 10 6 /ml) were incubated in a 24 multi-well dish (Nunc, Roskilde, Denmark). The synthetic phosphorothioate oligodeoxyribonucleotides were added at the concentration of 80 g/ml on day 0 and 40 g/ml on day 1, day 2 and day 3, and the viable cell number was counted on day 2 to day 4.
Antisense oligodeoxyribonucleotide preparation
Modified phosphorothioate oligodeoxyribonucleotides were synthesized and purified by reverse-phased high performance liquid chromatography as described previously. 16 The sequences of oligonucleotides used are listed in Table 1 . One mg of each oligonucleotide was suspended in 250 l of phosphate-buffered saline (PBS) and kept at −20°C.
DNA fragmentation assay and morphological examination
For DNA fragmentation assay, low molecular weight chromosomal DNA was extracted from 1 × 10 6 cells, separated by 2% agarose gel electrophoresis and visualized by ethidium bromide as described previously. 17 For morphological examination, cells were fixed on slide glasses using a cytospin apparatus (Cytospin 2; Shandon, Pittsburgh, PA, USA) and stained by Wright and Giemsa solution. Alternatively, slide glass-fixed cells were treated with a mixture of acetone/methanol (1:3) for 5 min at room temperature and incubated with 4 g/ml of H33342 (Calbiochem, La Jolla, CA, USA) for 10 min at room temperature. The chromatin structures of the cells were examined by fluorescence light microscopy. Cells were simultaneously observed by light microscopy with Normarsky differentiated interference contrast (Olympus Optical, Tokyo, Japan).
Cell cycle analysis
After oligonucleotide treatment, 5 × 10 5 cells were collected, washed with PBS and fixed with 70% ice-cold ethanol for 4 h. After treatment with RNase A (100 g/ml) (Sigma Chemical, St Louis, MO, USA) for 30 min at 37°C, DNA was stained with 50 g/ml of propidium iodide (Sigma). Cell cycle analysis was performed by FACScalibur (Becton Dickinson, Mountain View, CA, USA) with ModiFit LT program.
Antiserum and Western blotting
Anti-CREB antiserum was prepared as described previously. 18 Briefly, rabbits were immunized by keyhole limpet hemocyanin-conjugated synthetic C-terminal CREB peptide Table 1 were added to HL-60 cells for 4 days (day 0, 80 g/ml; day 1 to day 3, 40 g/ml). Viable cell number was counted on day 2, day 3 and day 4. (b) Antisense-1 and antisense-3 oligonucleotides were added to HL-60 cells for 3 days and the viable cell number was counted on day 3. The horizontal axis indicates the total dose of oligonucleotide used.
(QNKTLIEELKALKDLYCHKSD). The titer of antiserum was evaluated by ELISA assay. For Western blotting, 1 × 10 6 cells were lysed with 200 l of 2 × Laemmli's sample buffer and boiled for 5 min. Ten l of the lysate (ie 5 × 10 4 cells) was used for SDS-PAGE with 12.5% gel (acrylamide:bisacrylamide = 40:0.8). Transfer to the membrane, first and second antibody reactions, and the final detection procedure were performed as described previously. 18 The CREB protein was detected as a 45 kDa band downward to a 47 kDa non-specific band. 18 
Dot blot analysis
HL-60 cells were treated with PBS, 80 g/ml of antisense-1 or 80 g/ml sense-1 oligonucleotides at day 0 and PBS, 40 g/ml of antisense-1 or 40 g/ml sense-1 oligonucleotides at day 1. After a further 20 h incubation, messenger RNA was extracted from 4 to 8 × x10 7 cells by Fast Track 2.0 Kit (Invitrogen, Carlsbad, CA, USA) and suspended in 20 l of 0.1% diethyl pyrocarbonate-containing water. Four l of mRNA solution was mixed with the denaturing buffer (final concentration 50% formamide, 10% formalin, 0.1% SDS, 1 mM EDTA, 20 mM sodium phosphate buffer) and spotted to Hybond-N+ nylon membrane (Amersham Pharmacia Biotech UK, Buckingham, UK). Hybridization was performed using the CREB probe, which was prepared by random labeling of CREB cDNA (XbaI/BamHI fragment of pCG-CREB 18 ) with 32 P-dCTP cDNA, or the GAPDH probe, which was kindly provided by
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TUNEL (TdT-mediated dUTP-biotin nick-end labeling) assay
Antisense or sense oligonucleotide-treated cells were fixed at day 4 on glass slides by cytospin apparatus. Cells that were treated with 1 g/ml of actinomycin D for 5 h were fixed in the same way. Cells were stained by FITC-dUTP and terminal deoxytidyl transferase (TdT) using MEBSTAIN Apoptosis Kit Direct (Medical & Biological Laboratories, Nagoya, Japan) according to the guide included and examined under fluorescent microscopy.
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Results
CREB antisense oligonucleotides inhibit the growth of leukemia cells and subsequently induce non-apoptotic cell death
To study the role of CREB in hematopoietic cell growth, we prepared three pairs of CREB antisense and sense phosphorothioate oligodeoxyribonucleotides (PS-ODNs) ( Table 1) . They were added to culture medium of human leukemia HL-60 cells for 4 days (80 g/ml on day 0, 40 g/ml on days 1 to 3) and the viable cell number was counted during that time. As shown in Figure 1a , cell growth was completely blocked at day 2 in all antisense-treated cells, while no significant growth suppression was detected by sense PS-ODN treatment. The antisense-mediated growth suppression was observed in a dose-dependent manner (Figure 1b) . On day 4, we observed trypan blue-positive dead cells in antisense-treated samples together with an emergence of sub-diploid fraction in DNA content analysis (Figure 2a ). The dead cells had prominent nuclear fragmentations as demonstrated by Weight-Giemsa staining (Figure 2b ) and Hoechst fluorochrome staining ( Figure  2c ). These prominent nuclear fragmentations are usually observed either in apoptosis, death executed by specific intracellular events including internucleosomal DNA cleavage forming 3Ј-OH DNA end, or in mitotic catastrophe, death associated with premature M phase entry after G2/M arrest. First, we examined the possible induction of apoptosis by performing DNA fragmentation assay, a test to detect the internucleosomal DNA breakdown, and TUNEL assay, a test to detect the 3Ј-OH DNA end. We found that the antisensetreated cells showed no apoptotic internucleosomal DNA cleavage (Figure 2d ). Moreover, they were negative in the TUNEL assay (Figure 2e , middle) in contrast to the actinomycin D-treated apoptotic cells (Figure 2e, bottom) . Thus, the antisense-treated cells did not undergo apoptosis. We next examined the possible occurrence of mitotic catastrophe by performing daily cell cycle analysis. As shown in Figure 2f , we could detect no accumulation of G2/M phase but found a mild accumulation of S phase with a prominent G1 reduction during the time course, suggesting that the S phase progression was impaired in antisense-treated cells. Thus, the antisense ODN-treated cells did not undergo mitotic catastrophe. Nonetheless, mitotic cells were actually detected on day 4 ( Figure  2b , open arrowheads) and an elevation in prophased cell number was detected at day 3 in antisense-treated samples (7.2%) compared to the sense-treated ones (2.5%) (Figure 2g) . Thus, antisense-treated cells may have entered M phase before undergoing death with nuclear fragmentation. Actually, abnormally featured mitotic cells were recurrently found in the antisense-treated samples. There were cells which displayed intermediate structures of condensed prometaphase chromosomes and fragmented nuclei (Figure 2h , middle) in addition to cells with typical nuclear fragmentation (Figure 2h , left). Moreover, condensing prophase chromosomes, prometaphase chromosomes and fragmented nuclei were detected in a single cell (Figure 2h, right) . These findings suggest that there may be a disorder in M phase initiation in the antisensetreated cells and the cells died at M phase rather than S phase.
Thus, CREB antisense PS-ODNs inhibit the growth of HL-60 cells and subsequently induce a non-apoptotic but a mitotic catastrophe-like cell death.
Growth inhibition was executed by a non-antisense mechanism
It is known that synthetic PS-ODNs often influence the activities of cells through non-antisense mechanisms. [8] [9] [10] [11] [12] [13] [14] [15] To determine whether CREB antisense PS-ODN-mediated cell death was mediated by an antisense mechanism, CREB protein expression was examined by Western blotting. We found, however, no reduction in CREB protein expression on day 2 or day 4 ( Figure 3 ). We also examined CREB message expression by dot hybridization. We found no suppression in CREB message expression in an antisense-treated sample (the relative CREB/GAPDH values were 1, 0.89 and 0.72 in PBS-, antisense-1-and sense-1-treated samples, respectively). Furthermore, competitive polymerase chain reaction after reverse transcription (RT-PCR) showed no significant reduction of CREB message expression in antisense-treated samples (data not shown). Thus, growth inhibition by CREB antisense PS-ODNs was mediated by a non-antisense mechanism. We next examined the possibility that the growth inhibition was carried out by a sequence-specific mechanism, which is called aptameric mechanism, as reported in cases of bcr-abl, 12 c-myc, 13 c-myb 13, 14 and HIV 15 antisense. We synthesized an 11 mer oligonucleotide named AS-1.3, whose sequence is shared by antisense-1 and antisense-2. This oligonucleotide was added to HL-60 cells and the growth inhibitory potential was examined. As shown in Figure 4 , AS-1.3 did not significantly influence the growth of HL-60. Thus, it would be unlikely that the anti-proliferative effect was executed by a sequence-specific mechanism.
Lastly, we examined whether certain hybridization-dependent mechanisms mediated the growth inhibition. To address this point, we performed mutation analysis. Point mutations or deletions were added to the three antisense PS-ODNs as shown in Table 2 and their growth inhibitory effects were examined. As shown in Figure 4 , a good correlation between the growth inhibitory potential and the melting temperature was detected, suggesting that a certain hybridization-dependent mechanism executed the growth inhibition.
Thus, CREB antisense PS-ODNs inhibit the growth of leukemia cells by a non-antisense mechanism but also by a certain hybridization-dependent mechanism.
CREB antisense PS-ODNs inhibit growth of other leukemia cell lines and primary leukemia cells
We next investigated whether CREB antisense-mediated growth suppression is specific to HL-60 cells or general among various leukemia cells. CREB antisense or sense PSODNs were added to the three myeloid leukemia cell lines and the primary leukemia cells isolated from two patients. As shown in Figure 5 , the growth of Kasumi-1 AML (M2) line (Figure 5a ), K562 CML line (Figure 5b ), OCI-AML1a AML (M4) line (Figure 5c ) and bone marrow mononuclear cells isolated from two patients with AML (M2) (Figure 5d ) and CML in blastic crisis (CML-BC) (Figure 5e ) were all inhibited by CREB antisense PS-ODN, while sense PS-ODN did not significantly affect the cell growth.
Thus, CREB antisense PS-ODNs inhibit the growth of diverse leukemia cells.
Normal human bone marrow CD34 + cells and peripheral blood lymphocytes are resistant to CREB antisense-mediated growth suppression
We next examined the effects of CREB antisense oligonucleotides on the growth of normal human hematopoietic cells. The Correlation between melting temperature and growth-inhibiting potential. A series of CREB antisense mutants, whose sequences are shown in Table 2 , were synthesized and added to HL-60 cells for 4 days (day 0, 40 g/ml; day 1 to day 3, 20 g/ml). The viable cell numbers were counted on day 4. The melting temperature (Tm) was roughly estimated using the following formula (°C) = 2 (A + T) + 4 (G + C), where (A + T) is the number of A and T residues in the oligonucleotides and (G + C) is the number of G and C residues. AS indicates the antisense strand and S indicates the sense strand. The complimentary oligonucleotide pairs were subscribed with identical numbers after hyphenation.
Table 2
Sequences of mutated oligonucleotides TGG TCA TTT AG  AS-2  TGG TCA TTT AGT TAC CGG TG  AS-2.1  TGG TCA TTT ACT TAG CGG TG  AS-2.2  TGG TGA TTT ACT TAG CCG TG   AS-3  GCT TTC GTT CAC GGC CCG GA  S-3  TCC GGG CCG TGA ACG AAA GC  AS-3.1 GCT TTC CTT CAC GGC GCG GA S-3.1 TCC GCG CCG TGA AGG AAA GC AS-3.2 GCT TTC CTT GAC GGC GCC GA S-3.2 TCG GCG CCG TCA AGG AAA GC AS-3. 3 GCT TTC GTT CAC GGC CC S-3.3 GGG CCG TGA ACG AAA GC AS-3. 4 GCT TTC GTT CAC GG S-3. 4 CCG TGA ACG AAA GC AS-3.5
GCT TTC GTT CA S-3.5
TGA ACG AAA GC AS-3. 6 GCT TTC GT S-3 ACG AAA GC AS-3.7
GCT TT S-3.7
AAA GC Mutated sites are underlined.
bone marrow CD34 + cells isolated from a normal volunteer were cultured in the presence of antisense or sense PS-ODN. As shown in Figure 6a , the proliferation rate on day 4 did not significantly differ among PBS-, antisense-and sense-treated samples, indicating that CD34
+ cells were resistant to antisense-mediated growth suppression. We also examined the effect of antisense PS-ODN on the growth of PHA-treated peripheral blood lymphocytes. Although there was a certain amount of non-specific cytotoxicity of PS-ODNs detected, we could not find any antisense-specific growth suppressive effect in PHA-treated lymphocytes (Figure 6b) . Thus, the growth inhibitory effect of CREB antisense PSODNs was specific to leukemia cells, and the normal hematopoietic cells were resistant to the antisense-mediated growth inhibition.
Discussion
We have demonstrated that synthetic CREB antisense PSODNs, but not sense PS-ODNs, inhibit the growth of human leukemia cells. We have also shown that normal hematopoietic progenitor cells and normal peripheral lymphocytes are resistant to antisense PS-ODNs-mediated growth inhibition.
As we have shown, growth inhibition is executed by a nonantisense mechanism but also by a hybridization-dependent mechanism. There could be three possibilities for this phenomenon. First, the antisense PS-ODNs hybridized to certain messages or genes that are distinct to CREB. We found, however, no genes that contain sense-1, sense-2 and sense-3 sequences within genetic databases. Secondly, antisense PSODNs hybridized to certain chromosomal loci that have no genetic information but are important for cell growth such as DNA replication and repair. We have, however, no data to support this possibility. Whether there exists a sequence identical to sense-1, sense-2 and sense-3 within the whole human genome is a matter of interest. Finally, the antisense PS-ODNs bound to certain peptide or lipid factors which are involved in the growth control of leukemia cells and, modifying their functions, led to cell death. Of course, we could not com- pletely rule out the possibility that there exists a cryptic consensus oligonucleotide sequence responsible for growth inhibition within CREB PS-ODNs. Further investigations are required for its evaluation.
In the present study, we showed that antisense-treated cells died not by apoptosis, but by an unknown mitotic catastrophe-like mechanism with impaired S phase progression and also abnormal mitotic features. It is reported that X-rayirradiated Hela cells showed a delay in S phase progression and subsequently underwent mitotic catastrophe. 19 By analogy to this case, it might be possible that a delay in S phase progression caused by CREB antisense PS-ODNs would result in a dysregulated mitosis process. In Hela cells, p53 protein is continuously destroyed 20 and p53 is an important factor for the G2 checkpoint as well as the G1 checkpoint. 21 Thus, delayed S phase progression would bring about premature M phase entry through the dysfunction of p53. It is known that PS-ODNs bind non-specifically to a variety of intracellular proteins including nucleic acid polymerases. It might be possible that CREB antisense ODNs were hybridized to DNA polymerase and disturbed S phase progression, which then causes premature M phase entry in G2 checkpoint dysregulated leukemic cells including p53 null HL-60.
The most important point concerning the effects of CREB antisense PS-ODNs is that the normal hematopoietic progenitor CD34 + cells and normal peripheral lymphocytes are resistant to the antisense-mediated growth suppression. This is particularly important when a clinical application of CREB antisense PS-ODNs is considered. To date, we do not know why normal cells are resistant to PS-ODNs-mediated growth inhibition. We observed that certain leukemia cell lines including megakaryoblastic UT7 and MO7e and monoblastic U937 were also resistant to antisense PS-ODNs (preliminary observation by KS). It may be possible that the effects of antisense PS-ODNs depend on the lineage of leukemia cells: the most potent effects on AML (HL-60, Kasumi-1, OCI-AML1a and primary leukemia cells from a patient) and CML-BC (K562 and primary leukemia cells from a patient) and the weakest effects on normal hemato-progenitor cells and M7 AML. Alternatively, the ability to determine the G2 and/or M checkpoint, in which p53, ATM, BRCA and Chks are involved, may decide the destiny of antisense-treated cells of whether they undergo death with nuclear fragmentation or live to grow. However, specific toxicity of antisense PS-ODNs to certain types of leukemia cells may not be a disadvantage, but rather, a benefit for clinical usage because broad-spectrum in vivo side-effects might be avoided. More detailed examinations are required for the evaluation of in vivo toxicity of CREB antisense PS-ODNs.
Figure 6
Normal bone marrow CD34 + cells and peripheral blood lymphocytes cells are resistant to antisense-mediated growth inhibition. (a) Bone marrow CD34
+ cells from a normal volunteer were cultured at the density of 3.5 × 10 4 /ml. Antisense-1 (AS) or sense-1 (S) was added for 4 days as described in Figure 1a and the viable cell number was counted at day 4. The vertical axis indicates the fold increase to the starting cell number (indicated as 'Before') of PBS-, antisense-1 (AS) and sense-1 (S)-treated samples. The results from three independent experiments are shown. (b) Peripheral blood lymphocytes were isolated from a normal volunteer and cultured at the density of 1 × 10 6 /ml in the presence of PHA. Antisense-1 or sense-1 was added for 4 days. The cell growth was estimated by relative WST-reducing activity to that of a PHA-untreated sample on day 4. The results from three independent experiments are shown.
